Search Results
Mar 02, 2026, 07:00 ET AAON Reports Fourth Quarter and Full Year 2025 Results
place, and with operational execution continuing to improve, we expect 2026 sales to grow 18%-20%, with gross margin of 29%-31%. We also anticipate SG&A expenses as a percentage of sales will be approximately 16% and expect depreciation and amortization expenses of $95-$100 million."
More news about: AAON
Feb 27, 2026, 10:15 ET Metal Fabrication Market size to Hit USD 32.47 Billion by 2032 at 4.7% CAGR, Reports Maximize Market Research
spotlighting robust demand for CNC machining and heavy fabrication services.Yamazaki Mazak Corporation launched its advanced QRX‑50MSY SG compact dual‑spindle CNC lathe in Dec 2025, enhancing precision machining and cycle efficiency for metal fabrication and component
More news about: Maximize Market Research Pvt. Ltd.
Feb 27, 2026, 07:30 ET Alpha Announces Financial Results for Fourth Quarter and Full Year 2025
SG&A5$53
More news about: ALPHA METALLURGICAL RESOURCES, INC.
Feb 26, 2026, 16:30 ET BOARDWALKTECH REPORTS THIRD QUARTER FISCAL 2026 FINANCIAL RESULTS
represented an 18% sequential improvement over Q2-FY26 due to an increase in revenues and a decrease in costs. Total selling, general and administration ("SG&A") expenses in Q3-FY26 totaled $1.1 million, a $0.1 million decrease from $1.2 million reported in Q2-FY26 and a $0.3 million decrease from the $1.4
More news about: Boardwalktech Software Corp.
Feb 26, 2026, 09:48 ET 再鼎醫藥公佈2025年第四季度及全年財務業績和近期公司進展
160萬美元，2024年同期為5,230萬美元。2025年全年研發開支為2.209億美元，2024年同期為2.345億美元。第四季度研發開支的增加主要源於臨床研究的推進。全年研發開支下降主要得益於戰略資源優化調整帶來的人員成本下降。2025 年第四季度的銷售、一般及行政 (SG&A) 開支為 7,300 萬美元，2024 年同期為8,260 萬美元。2025年全年的SG&A開支為 2.776 億美元， 2024 年同期為 2.987 億美元。這一下降主要由於戰略資源優化調整所帶來一般及行政開支的下降。2025 年第四季度和 2025 年全年的經營虧損分別為
More news about: 再鼎醫藥
Feb 26, 2026, 08:00 ET Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
and Non-GAAP research and development (R&D) and selling, general and administrative (SG&A) expense reduction goals and is improving future targets.Non-GAAP full year R&D and SG&A expenses, net of R&D reimbursements and at midpoint of range, are now targeted to be
More news about: Novavax, Inc.
Feb 26, 2026, 06:59 ET Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
free cash flow excluding the impact of transaction-related and restructuring-related costs; adjusted R&D and as a % of total revenues, adjusted SG&A and as a % of total revenues, adjusted earnings from operations, adjusted interest expense, adjusted other income, net, adjusted effective tax rate,
More news about: Viatris Inc.
Feb 26, 2026, 06:30 ET HORMEL FOODS REPORTS FIRST QUARTER FISCAL 2026 RESULTS
exports, led by SPAM® luncheon meat. International segment profit increased in the first quarter of fiscal 2026 as lower SG&A spend and growth in China were partially offset by lower export margins.ADDITIONAL FINANCIAL DETAILS – FIRST QUARTER FISCAL 2026Income
More news about: Hormel Foods Corporation
Feb 26, 2026, 06:00 ET Clear Channel Outdoor Holdings, Inc. Reports Results for the Fourth Quarter and Full Year of 2025
2024, respectively.Direct operating and SG&A expenses for the fourth quarter of 2025, compared to the same period in 2024:America: Direct operating and SG&A expenses up 3.1%:Site lease expense up 6.5% to $98.7 million
More news about: Clear Channel Outdoor Holdings, Inc.
Feb 26, 2026, 06:00 ET Primo Brands Reports 2025 Fourth Quarter and Full Year Results
merger transaction and non-recurring integration costs attributable to BlueTriton Brands.SG&A expenses increased 1.5% to $341.0 million compared to $335.9 million, primarily driven by SG&A expense attributable to Primo Water due to the merger transaction, partially offset by nonrecurring
More news about: Primo Brands Corporation
Feb 26, 2026, 05:00 ET Daqo New Energy Announces Unaudited Fourth Quarter and Fiscal Year 2025 Results
because of a decrease in production cost.Selling, general and administrative expensesSelling, general and administrative (SG&A) expenses were $18.7 million, compared to $32.3 million in the third quarter of 2025 and $29.4 million in the fourth quarter of 2024. The decrease
More news about: Daqo New Energy Corp.
Feb 25, 2026, 19:04 ET Genomma Lab Internacional Announces Results for the Fourth Quarter and Full Year 2025
productivity initiatives, reflecting strong operational resilience despite deleveraging pressures. EBITDA reached a 22.1% margin in Q4 2025 as lower SG&A partially offset the operational deleverage following the significant reduction in Mexico sell-in during the quarter.Net Income from Continuous
More news about: Genomma Lab Internacional, S.A.B. de C.V.
Feb 25, 2026, 16:07 ET OUTFRONT Media Reports Fourth Quarter And Full Year 2025 Results
guaranteed minimum annual payments to the New York Metropolitan Transportation Authority (the "MTA").Selling, General and Administrative expenses ("SG&A") of $111.2 million increased $1.6 million, or 1.5%, due primarily to higher professional fees, a higher provision for doubtful accounts, and travel
More news about: OUTFRONT Media Inc.
Feb 25, 2026, 16:05 ET HAMILTON BEACH BRANDS HOLDING COMPANY ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 RESULTS
our U.S. Consumer business, and a product margin benefit from the timing of price increases. Selling, general and administrative expenses (SG&A) increased to $34.7 million compared to $32.1 million. The increase was primarily driven by higher performance-based compensation expense related
More news about: Hamilton Beach Brands Holding Company
Feb 25, 2026, 13:00 ET Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
fourth quarter of 2024. R&D expenses were $21.8 million for the fourth quarter of 2025, compared to $20.0 million for the fourth quarter of 2024. SG&A expenses were $181.1 million for the fourth quarter of 2025, compared to $147.9 million for the fourth quarter of 2024.Income from operations
More news about: Penumbra, Inc.
Feb 24, 2026, 16:05 ET Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
administrative (SG&A) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2025 compared to 2024, primarily due to Xyrem antitrust litigation settlements of $234 million, the Avadel litigation settlement of $90 million and higher compensation-related expenses. SG&A expenses, on
More news about: Jazz Pharmaceuticals plc
Feb 24, 2026, 16:05 ET Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
administrative (SG&A) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2025 compared to 2024, primarily due to Xyrem antitrust litigation settlements of $234 million, the Avadel litigation settlement of $90 million and higher compensation-related expenses. SG&A expenses, on
More news about: Jazz Pharmaceuticals plc
Feb 24, 2026, 16:01 ET Axon reports Q4 2025 revenue of $797 million, up 39% year over year
compensation expense.COGS of $335 million, or 42.1% of revenue, included $16 million in stock-based compensation expense.SG&A expense of $317 million, or 39.8% of revenue, included $124 million in stock-based compensation expense.R&D expense of $194 million,
More news about: Axon
Feb 24, 2026, 07:00 ET Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2025 Results
70.8SG&A as a percentage of revenue43.6 %
More news about: Avanos Medical
Feb 24, 2026, 07:00 ET Keurig Dr Pepper Reports Q4 and Full Year 2025 Results and Provides 2026 Outlook
operating income growth was driven by net sales growth and productivity savings, partially offset by the impact of inflationary pressures and higher SG&A costs.GAAP net income increased 44.3% to $2.1 billion, or $1.53 per diluted share, including a favorable year-over-year impact
More news about: Keurig Dr Pepper
Feb 24, 2026, 06:00 ET China Yuchai International Announces Unaudited 2025 Second Half-Year and Full Year Financial Results
8.3% of the revenue in 2H 2025, as compared with RMB 726.0 million, or 8.2% of the revenue in 2H 2024.Selling, general and administrative ("SG&A") expenses increased by 4.9% to RMB 1.1 billion (US$ 157.7 million) from RMB 1.0 billion in 2H 2024. This increase was mainly due to increased personnel
More news about: China Yuchai International
Feb 23, 2026, 16:05 ET BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
Non-GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP R&D expenses and Non-GAAP SG&A expenses are defined by the company as GAAP R&D expenses and GAAP SG&A expenses, respectively, excluding stock-based compensation expense and, in certain periods, certain other specified
More news about: BioMarin Pharmaceutical Inc.
Feb 23, 2026, 16:05 ET V2X Reports Fourth Quarter 2025 Results
represents revenue less both cost of revenue and selling, general and administrative (SG&A) expenses. Cost of revenue consists of labor, subcontracting costs, materials, and an allocation of indirect costs. SG&A expenses consist of indirect labor costs (including wages and salaries for executives
More news about: V2X, Inc.
Feb 20, 2026, 17:59 ET Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
National Comorbidity Survey (NSC). (2017, August 21). Potkin SG, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
More news about: Vanda Pharmaceuticals Inc.
Feb 19, 2026, 16:46 ET Burnham Holdings, Inc. Announces Fourth Quarter 2025 Financial Results
Commercial businesses. Year-to-date gross margin for 2025 was 23.0%, up from 22.3% for 2024. Strategic SG&A Investment: Adjusted selling, general, and administrative expenses (SG&A) as a percentage of net sales were 13.6% in the fourth quarter and 17.0% for the full year 2025. The year-over-year
More news about: Burnham Holdings, Inc.